FDA Grants Accelerated Approval to Repotrectinib for Adult and Pediatric Patients With Ntrk Gene Fusion-Positive Solid Tumors
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.